$50 million US aid to vaccine maker

October 25, 2021 10:34 pm | Updated October 26, 2021 12:03 am IST - HYDERABAD

U.S. International Development Finance Corporation COO David Marchick and Biological E Limited’s managing director Mahima Datla ink an agreement as diplomats from Quad countries look on, in Hyderabad on Monday.

U.S. International Development Finance Corporation COO David Marchick and Biological E Limited’s managing director Mahima Datla ink an agreement as diplomats from Quad countries look on, in Hyderabad on Monday.

The US government financial arrangement of 50 million dollars to expand Hyderabad-based Biological E. Limited’s capacity to produce COVID-19 vaccine was finalised on Monday.

United States International Development Finance Corporation (DFC) COO David Marchick and Biological E Limited’s managing director Mahima Datla signed the agreement at an event held in Hyderabad.

This work is in support of the commitment set out by US President Biden and his counterparts in the Quad - Australia, India, Japan, and the United States, as per a press release.

The company’s MD Mahima Datla said that the DFC support and funding is playing an instrumental role in ensuring access to vaccines not just for India but for rest of the world.

“We are currently in the process of building enhanced vaccine manufacturing capacity to augment COVID vaccine availability for the entire Asia-Pacific region and indeed the world,” she said at the event. The DFC’s COO said that the investment with Biological E has potential to produce more than a billion doses to the world.

India’s Ministry of External Affairs Joint Secretary Vani Rao, United States Consul General Joel Reifman, Japanese Consul General Taga Masayuki, Australian Consul General Sarah Kirlew, Telangana’s IT and Industry principal secretary Jayesh Ranjan and others participated in the event.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.